In this educational video, Dr. David Eberhard, Senior Medical Director in Oncology at Illumina, explains what comprehensive genomic profiling (CGP) is and how it provides cancer patients and oncologists with a powerful testing approach to help identify biomarkers for therapy selection and eligibility for clinical trials. In addition, he discusses how CGP brings many benefits to a pathology lab, and is the most effective approach for biomarker profiling in a world where new cancer therapy biomarkers are being developed at a rapid pace.

Learn more about the future in Oncology: emea.illumina.com/areas-of-interest/cancer/future-of-ngs-in-oncology.html

Subscribe to the Illumina video channel youtube.com/subscription_center?add_user=IlluminaInc

A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.

*Data calculations on file. Illumina, Inc., 2015.

View customer spotlight videos
youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79

View Illumina webinars
youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ

View Illumina product videos
youtube.com/playlist?list=PLKRu7cmBQlaj6YuZmkfxZcT9twqDgP2Xd

View Illumina support videos
youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM